Changes in the composition of the gut microbiota and content of microbial-derived uremic toxins in patients undergoing hemodialysis

Abstract

Recent data highlight a significant role of the gut microbiota in the pathogenesis of chronic kidney disease, particularly in its terminal stage. However, little is known about the features of intestinal dysbiosis in people undergoing programed hemodialysis. Changes in the intestinal microbiota and blood levels of uremic toxins of microbial origin in patients with terminal renal insufficiency receiving hemodialysis were analyzed. This cross-sectional study included 80 patients receiving hemodialysis and 20 individuals with normal kidney function. The state of the microbiocenosis of the colon was studied using a polymerase chain reaction with a commercial set Colonoflor 16 (premium) manufactured by Alfalab (Russia). Serum levels of trimethylamine and its metabolite trimethylamine-N-oxide were determined by liquid chromatography/mass spectrometry. The concentrations of indoxyl sulfate and p-cresyl sulfate were evaluated by enzyme immunoassay according to the instructions of a commercial kit. In patients undergoing programed hemodialysis, increased colonization of enterococci was combined with the reduction of lacto and bifidophlora, E. coli, ruminococci, bacteria producing short-chain fatty acids (Faecalibacterium prausnitzii, Eubacterium rectale, Roseburia inulinivorans, and Blautia spp.) and microorganisms involved in maintaining the integrity of the intestinal barrier (Bacteroides thetaomicron and Akkermansia muciniphila). In addition, high titer levels of representatives of opportunistic and even pathogenic flora were often found in this group. Intestinal dysbiosis in patients undergoing programed hemodialysis was accompanied by a significant increase in the concentration of uremic toxins in the blood. Compared with individuals with normal renal function, the trimethylamine level in patients undergoing programed hemodialysis was increased 22 times; trimethylamine-N-oxide, 23 times; indoxyl sulfate, 21 times; and p-cresyl sulfate, 5 times. Thus, patients receiving hemodialysis exhibited pronounced pathological changes in intestinal microbiocenosis, accompanied by a significant increase in serum levels of uremic toxins of microbial origin.

Keywords

intestinal microbiota / intestinal dysbiosis / the intestinal barrier / microbiocenosis / uremic toxins / chronic kidney disease / tubulointerstitial nephritis / programmatic hemodialysis

References

[1] Mishima E, Abe T. Gut microbiota dynamics and uremic toxins. Toxins (Basel). 2022;14(2):146. doi: 10.3390/toxins14020146

[2] Mishima E., Abe T. Gut microbiota dynamics and uremic toxins // Toxins (Basel). 2022. Vol. 14, N. 2, ID 146. doi: 10.3390/toxins14020146

[3] Mishima E, Abe T. Gut microbiota dynamics and uremic toxins. Toxins (Basel). 2022;14(2):146. doi: 10.3390/toxins14020146

[4] Tkachenko EI, Grinevich VB, Gubonina IV, et al. Disease as a result of violations of the symbiotic relationship between the host and the microbiota with pathogens. Bulletin of the Russian Military Medical Academy. 2021;23(2):243–252. EDN: OIYFED doi: 10.17816/brmma58117

[5] Ткаченко Е.И., Гриневич В.Б., Губонина И.В., и др. Болезни как следствие нарушений симбиотических взаимоотношений организма хозяина с микробиотой и патогенами // Вестник Российской военно-медицинской академии. 2021. Т. 23, № 2. С. 243–252. EDN: OIYFED doi: 10.17816/brmma58117

[6] Tkachenko EI, Grinevich VB, Gubonina IV, et al. Disease as a result of violations of the symbiotic relationship between the host and the microbiota with pathogens. Bulletin of the Russian Military Medical Academy. 2021;23(2):243–252. EDN: OIYFED doi: 10.17816/brmma58117

[7] Pyatchenkov MO, Vlasov AA, Sherbakov EV, et al. Features of assessing the intestinal barrier permeability in chronic kidney disease. Experimental and clinical gastroenterology journal. 2022;(11):46–59. EDN: BLYDXK doi: 10.31146/1682-8658-ecg-207-11-46-59

[8] Пятченков М.О., Власов А.А., Щербаков Е.В., и др. Особенности оценки проницаемости кишечного барьера при хронической болезни почек // Экспериментальная и клиническая гастроэнтерология. 2022. № 11. С. 46–59. EDN: BLYDXK doi: 10.31146/1682-8658-ecg-207-11-46-59

[9] Pyatchenkov MO, Vlasov AA, Sherbakov EV, et al. Features of assessing the intestinal barrier permeability in chronic kidney disease. Experimental and clinical gastroenterology journal. 2022;(11):46–59. EDN: BLYDXK doi: 10.31146/1682-8658-ecg-207-11-46-59

[10] Pyatchenkov MO, Salikova SP, Sherbakov EV, Vlasov AA. The state of the intestinal microbial-tissue complex in patients with chronic kidney disease. Bulletin of the Russian Military Medical Academy. 2023;25(1):155–164. EDN: RBHWNK doi: 10.17816/brmma124822

[11] Пятченков М.О., Саликова С.П., Щербаков Е.В., Власов А.А. Состояние микробно-тканевого комплекса кишечника у больных хронической болезнью почек // Вестник Российской военно-медицинской академии. 2023. Т. 25, № 1. С. 155–164. EDN: RBHWNK doi: 10.17816/brmma124822

[12] Pyatchenkov MO, Salikova SP, Sherbakov EV, Vlasov AA. The state of the intestinal microbial-tissue complex in patients with chronic kidney disease. Bulletin of the Russian Military Medical Academy. 2023;25(1):155–164. EDN: RBHWNK doi: 10.17816/brmma124822

[13] Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237. doi: 10.1159/000360010

[14] Wong J., Piceno Y.M., DeSantis T.Z., et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD // Am J Nephrol. 2014. Vol. 39, N. 3. P. 230–237. doi: 10.1159/000360010

[15] Wong J, Piceno YM, DeSantis TZ, et al. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39(3):230–237. doi: 10.1159/000360010

[16] Voroneanu L, Burlacu A, Brinza C, et al. Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes-A systematic review. J Clin Med. 2023;12(5):1948. doi: 10.3390/jcm12051948

[17] Voroneanu L., Burlacu A., Brinza C., et al. Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes-A systematic review // J Clin Med. 2023. Vol. 12, N. 5. ID 1948. doi: 10.3390/jcm12051948

[18] Voroneanu L, Burlacu A, Brinza C, et al. Gut microbiota in chronic kidney disease: from composition to modulation towards better outcomes-A systematic review. J Clin Med. 2023;12(5):1948. doi: 10.3390/jcm12051948

[19] Vaziri ND, Zhao Y-Y, Pahl M. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016;31(5):737–746. doi: 10.1093/ndt/gfv095

[20] Vaziri N.D., Zhao Y.-Y., Pahl M. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment // Nephrol Dial Transplant. 2016. Vol. 31, N. 5. P. 737–746. doi: 10.1093/ndt/gfv095

[21] Vaziri ND, Zhao Y-Y, Pahl M. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant. 2016;31(5):737–746. doi: 10.1093/ndt/gfv095

[22] Sturov NV, Popov SV, Belikov II. Gut microbiota and the ways to correct it in chronic kidney disease. Indian J Nephrol. 2023;33(3): 162–169. doi: 10.4103/ijn.ijn_469_21

[23] Sturov N.V., Popov S.V., Belikov I.I. Gut microbiota and the ways to correct it in chronic kidney disease // Indian J Nephrol. 2023. Vol. 33, N. 3. P. 162–169. doi: 10.4103/ijn.ijn_469_21

[24] Sturov NV, Popov SV, Belikov II. Gut microbiota and the ways to correct it in chronic kidney disease. Indian J Nephrol. 2023;33(3): 162–169. doi: 10.4103/ijn.ijn_469_21

[25] Kornoukhova LA, Emanuel VL, Denisov NL. Routine methods of laboratory studies of intestinal microbiota: role and place in clinical practice. Russian journal of evidence-based gastroenterology. 2021;10(4):5–11. EDN: YKMKPG doi: 10.17116/dokgastro2021100415

[26] Корноухова Л.А., Эмануэль В.Л., Денисов Н.Л. Рутинные методы лабораторных исследований микробиоты кишечника: роль и место в практике // Доказательная гастроэнтерология. 2021. Т. 10, № 4. С. 5–11. EDN: YKMKPG doi: 10.17116/dokgastro2021100415

[27] Kornoukhova LA, Emanuel VL, Denisov NL. Routine methods of laboratory studies of intestinal microbiota: role and place in clinical practice. Russian journal of evidence-based gastroenterology. 2021;10(4):5–11. EDN: YKMKPG doi: 10.17116/dokgastro2021100415

[28] Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–315. doi: 10.1038/ki.2012.345

[29] Vaziri N.D., Wong J., Pahl M., et al. Chronic kidney disease alters intestinal microbial flora // Kidney Int. 2013. Vol. 83, N. 2. P. 308–315. doi: 10.1038/ki.2012.345

[30] Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013;83(2):308–315. doi: 10.1038/ki.2012.345

[31] Wehedy E, Shatat IF, Al Khodor S. The human microbiome in chronic kidney disease: a double-edged sword. Front Med (Lausanne). 2022;8:790783. doi: 10.3389/fmed.2021.790783

[32] Wehedy E., Shatat I.F., Al Khodor S. The human microbiome in chronic kidney disease: a double-edged sword // Front Med (Lausanne). 2022. Vol. 8. ID 790783. doi: 10.3389/fmed.2021.790783

[33] Wehedy E, Shatat IF, Al Khodor S. The human microbiome in chronic kidney disease: a double-edged sword. Front Med (Lausanne). 2022;8:790783. doi: 10.3389/fmed.2021.790783

[34] Zhao J, Ning X, Liu B, et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi: 10.1080/0886022X.2020.1864404

[35] Zhao J., Ning X., Liu B., et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review // Ren Fail. 2021. Vol. 43, N. 1. P. 102–112. doi: 10.1080/0886022X.2020.1864404

[36] Zhao J, Ning X, Liu B, et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112. doi: 10.1080/0886022X.2020.1864404

[37] Bhargava S, Merckelbach E, Noels H, et al. Homeostasis in the gut microbiota in chronic kidney disease. Toxins (Basel). 2022;14(10):648. doi: 10.3390/toxins14100648

[38] Bhargava S., Merckelbach E., Noels H., et al. Homeostasis in the gut microbiota in chronic kidney disease // Toxins (Basel). 2022. Vol. 14, N. 10. ID 648. doi: 10.3390/toxins14100648

[39] Bhargava S, Merckelbach E, Noels H, et al. Homeostasis in the gut microbiota in chronic kidney disease. Toxins (Basel). 2022;14(10):648. doi: 10.3390/toxins14100648

[40] Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018;67(8):1445–1453. doi: 10.1136/gutjnl-2017-314508

[41] Hänninen A., Toivonen R., Pöysti S., et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice // Gut. 2018. Vol. 67, N. 8. P. 1445–1453. doi: 10.1136/gutjnl-2017-314508

[42] Hänninen A, Toivonen R, Pöysti S, et al. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut. 2018;67(8):1445–1453. doi: 10.1136/gutjnl-2017-314508

[43] Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017;12:157–170. doi: 10.2217/fmb-2016-0130

[44] Tamanai-Shacoori Z., Smida I., Bousarghin L., et al. Roseburia spp.: a marker of health? // Future Microbiol. 2017. Vol. 12. P. 157–170. doi: 10.2217/fmb-2016-0130

[45] Tamanai-Shacoori Z, Smida I, Bousarghin L, et al. Roseburia spp.: a marker of health? Future Microbiol. 2017;12:157–170. doi: 10.2217/fmb-2016-0130

[46] Hu Q, Wu K, Pan W, et al. Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China. J Int Med Res. 2020;48(6): 1–12. doi: 10.1177/0300060520926033

[47] Hu Q., Wu K., Pan W., et al. Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China // J Int Med Res. 2020. Vol. 48, N. 6. P. 1–12. doi: 10.1177/0300060520926033

[48] Hu Q, Wu K, Pan W, et al. Intestinal flora alterations in patients with early chronic kidney disease: a case-control study among the Han population in southwestern China. J Int Med Res. 2020;48(6): 1–12. doi: 10.1177/0300060520926033

[49] Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. PNAS USA. 2019;116(26):12672–12677. doi: 10.1073/pnas.1904099116

[50] Henke M.T., Kenny D.J., Cassilly C.D., et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide // PNAS USA. 2019. Vol. 116, N. 26. P. 12672–12677. doi: 10.1073/pnas.1904099116

[51] Henke MT, Kenny DJ, Cassilly CD, et al. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. PNAS USA. 2019;116(26):12672–12677. doi: 10.1073/pnas.1904099116

[52] Belova IV, Khrulev AE, Tochilina AG, et al. Colon microbiocenosis and its correction in patients receiving programmed hemodialysis. Modern technologies in medicine. 2020;12(5):62–70. EDN: ZPWVRM doi: 10.17691/stm2020.12.5.07

[53] Белова И.В., Хрулев А.Е., Точилина А.Г., и др. Микробиоценоз толстой кишки пациентов, получающих лечение программным гемодиализом, и его коррекция // Современные технологии в медицине. 2020. Т. 12, № 5. С. 62–70. EDN: ZPWVRM doi: 10.17691/stm2020.12.5.07

[54] Belova IV, Khrulev AE, Tochilina AG, et al. Colon microbiocenosis and its correction in patients receiving programmed hemodialysis. Modern technologies in medicine. 2020;12(5):62–70. EDN: ZPWVRM doi: 10.17691/stm2020.12.5.07

[55] Noce A, Marchetti M, Marrone G, et al. Link between gut microbiota dysbiosis and chronic kidney disease. Eur Rev Med Pharmacol Sci. 2022;26(6):2057–2074. doi: 10.26355/eurrev_202203_28354

[56] Noce A., Marchetti M., Marrone G., et al. Link between gut microbiota dysbiosis and chronic kidney disease // Eur Rev Med Pharmacol Sci. 2022. Vol. 26, N. 6. P. 2057–2074. doi: 10.26355/eurrev_202203_28354

[57] Noce A, Marchetti M, Marrone G, et al. Link between gut microbiota dysbiosis and chronic kidney disease. Eur Rev Med Pharmacol Sci. 2022;26(6):2057–2074. doi: 10.26355/eurrev_202203_28354

[58] Pyatchenkov MO, Vlasov AA, Sherbakov EV, Salikova SP. Microbial-derived uremic toxins: role in the pathogenesis of comorbidities in patients with chronic kidney disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(3):7–15. EDN: DZGPXN doi: 10.22416/1382-4376-2023-33-3-7-15

[59] Пятченков М.О., Власов А.А., Щербаков Е.В., Саликова С.П. Уремические токсины микробного происхождения: роль в патогенезе коморбидной патологии у пациентов с хронической болезнью почек // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023. Т. 33, № 3. С. 7–15. EDN: DZGPXN doi: 10.22416/1382-4376-2023-33-3-7-15

[60] Pyatchenkov MO, Vlasov AA, Sherbakov EV, Salikova SP. Microbial-derived uremic toxins: role in the pathogenesis of comorbidities in patients with chronic kidney disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(3):7–15. EDN: DZGPXN doi: 10.22416/1382-4376-2023-33-3-7-15

[61] Kryukov EV, Potekhin NP, Chaplyuk AL, et al. Expert approaches to chronic kidney disease. Military medical journal. 2016;337(10): 13–18. EDN: XBTEMF doi: 10.17816/RMMJ73839

[62] Крюков Е.В., Потехин Н.П., Чаплюк А.Л., и др. Экспертные подходы при хронической болезни почек // Военно-медицинский журнал. 2016. Т. 337, № 10. C. 13–18. EDN: XBTEMF doi: 10.17816/RMMJ73839

[63] Kryukov EV, Potekhin NP, Chaplyuk AL, et al. Expert approaches to chronic kidney disease. Military medical journal. 2016;337(10): 13–18. EDN: XBTEMF doi: 10.17816/RMMJ73839

RIGHTS & PERMISSIONS

Eco-Vector